What Researchers Did
Researchers reviewed various types of radiation sensitizers and their mechanisms for increasing cellular radiosensitivity in radioresistant tumors.
What They Found
They found that pyrimidine analogues can increase cellular radiosensitivity up to a factor of 3 by incorporating into DNA. However, clinical trials using intra-arterial infusion of BUdR showed unsatisfactory long-term survival. The review also highlighted the potential of hypoxic cell sensitizers to address the radioresistance of hypoxic tumor cells.
What This Means for Canadian Patients
This review from 1986 explores early strategies to improve radiation therapy for radioresistant tumors by using sensitizing agents. While the specific agents and approaches discussed may have evolved, the underlying principle of overcoming tumor radioresistance remains relevant for optimizing cancer treatment.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
A significant limitation is that this is a review from 1986, meaning the information on clinical trials and experimental agents is outdated.